Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
36.67
-0.41 (-1.11%)
Mar 20, 2026, 2:15 PM EDT - Market open
Novo Nordisk Employees
Novo Nordisk had 69,505 employees as of December 31, 2025. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change (1Y)
-7,844
Growth (1Y)
-10.14%
Revenue / Employee
$699,061
Profits / Employee
$231,692
Market Cap
163.73B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVO News
- 5 hours ago - China expresses hopes over Novo Nordisk's presence in market - Reuters
- 5 hours ago - The Dow's losing streak, fertilizer prices, Novo Nordisk's new Wegovy shot and more in Morning Squawk - CNBC
- 11 hours ago - India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry - CNBC
- 16 hours ago - Novo Nordisk Wins FDA Approval For Higher-Dose Wegovy HD, Delivering 20.7% Weight Loss - Nasdaq
- 19 hours ago - Market Today: Big Banks, Novo Nordisk, Tesla in Focus - GuruFocus
- 23 hours ago - Novo Nordisk (NVO) Gains FDA Approval for New High-Dose Wegovy - GuruFocus
- 23 hours ago - A high dose of Wegovy helped people lose 21% of their weight. It was just approved. - Market Watch
- 23 hours ago - FDA approves higher dose of Wegovy - The Hill